Bortezomib for refractory autoimmunity in pediatrics.

[1]  Y. Qazi,et al.  Bortezomib in kidney transplantation , 2015, Current opinion in organ transplantation.

[2]  D. Roelen,et al.  Proteasome Inhibition Profoundly Affects Activated Human B Cells , 2013, Transplantation.

[3]  E. Woodle,et al.  Rapid Reduction in Donor-Specific Anti-Human Leukocyte Antigen Antibodies and Reversal of Antibody-Mediated Rejection With Bortezomib in Pediatric Heart Transplant Patients , 2012, Transplantation.

[4]  R. Alloway,et al.  Clinical and investigational use of proteasome inhibitors for transplant rejection , 2011, Expert opinion on investigational drugs.

[5]  R. Alloway,et al.  Proteasome inhibitor therapy for antibody‐mediated rejection , 2011, Pediatric transplantation.

[6]  E. Woodle,et al.  Proteasome inhibitor treatment of antibody-mediated allograft rejection , 2011, Current opinion in organ transplantation.

[7]  D. Esseltine,et al.  Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. , 2011, The Lancet. Oncology.

[8]  Andreas Radbruch,et al.  Long-lived autoreactive plasma cells drive persistent autoimmune inflammation , 2011, Nature Reviews Rheumatology.

[9]  P. Terasaki,et al.  Protective Immunity Remains Intact After Antibody Removal by Means of Proteasome Inhibition , 2010, Transplantation.

[10]  F. Moosig,et al.  Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma , 2010, Annals of the rheumatic diseases.

[11]  R. Alloway,et al.  Proteasome Inhibitor-Based Primary Therapy for Antibody-Mediated Renal Allograft Rejection , 2010, Transplantation.

[12]  R. Alloway,et al.  Proteasome inhibition for antibody-mediated rejection , 2009, Current opinion in organ transplantation.

[13]  P. Terasaki,et al.  Abrogation of Anti-HLA Antibodies via Proteasome Inhibition , 2009, Transplantation.

[14]  R. Alloway,et al.  Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection , 2008, Transplantation.

[15]  J. Kurtzberg,et al.  Posttransplant autoimmune hemolytic anemia and other autoimmune cytopenias are increased in very young infants undergoing unrelated donor umbilical cord blood transplantation. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  K. Fairfax,et al.  Plasma cell development: from B-cell subsets to long-term survival niches. , 2008, Seminars in immunology.

[17]  N. Puig,et al.  Autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation in adult patients , 2007, Bone Marrow Transplantation.

[18]  M. Marques,et al.  Laboratory evaluation and transfusion support of patients with autoimmune hemolytic anemia. , 2006, American journal of clinical pathology.

[19]  G. Giaccone,et al.  Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies , 2005, Cancer.

[20]  J. Neglia,et al.  Autoimmune haemolytic anaemia complicating haematopoietic cell transplantation in paediatric patients: high incidence and significant mortality in unrelated donor transplants for non‐malignant diseases , 2004, British journal of haematology.

[21]  Andreas Radbruch,et al.  Short-lived Plasmablasts and Long-lived Plasma Cells Contribute to Chronic Humoral Autoimmunity in NZB/W Mice , 2004, The Journal of Experimental Medicine.

[22]  M. Viele,et al.  Autoimmune hemolytic anemia in patients with SCID after T cell-depleted BM and PBSC transplantation , 1999, Bone Marrow Transplantation.

[23]  C. Bollard,et al.  Complications of transplant for nonmalignant disorders: autoimmune cytopenias, opportunistic infections, and PTLD. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[24]  P. Eckman,et al.  Bortezomib for refractory antibody-mediated cardiac allograft rejection. , 2009, Clinical transplants.